43 results about "Clostridium sp" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to a caproic acid-producing microbial composition and application thereof. According to the specific technical scheme, the microbial composition comprises caproic acid bacteria, clostridium and lactic acid bacteria. The caproic acid producing microbiome provided by the invention not only can be used for resourceful treatment of wastewater with high lactic acid concentration and reduction of environmental protection cost, but also can be used for construction and maintenance of pit mud, and provides a new practical reference for research of Luzhou-flavor liquor synthesis microbiome and preparation of artificial pit mud.

The invention belongs to the technical field of microorganisms, and discloses clostridium butyricum ML5358 and application thereof.The clostridium butyricum ML5358 provided by the invention has the preservation number of CGMCC No.37000. The strain can effectively relieve mouse colitis induced by DSS and remarkably reduce expression of colon tissue inflammatory factors Il-6 and Il-1beta, and the preservation number of the clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. In addition, skeletal muscle lipid metabolism can be regulated and controlled through the intestine-muscle axis, expression of fat synthesis and uptake related genes Srebf1, Acc1 and Fabp4 is specifically up-regulated, the content of intramuscular triglyceride is remarkably increased, and intramuscular fat deposition is promoted. According to the clostridium butyricum ML5358 and the application thereof, the functional limitation of traditional clostridium butyricum is broken through, and a new strain resource is provided for developing a novel microbial preparation or a feed additive capable of improving intestinal health and improving livestock and poultry meat quality.

The invention relates to the field of biological medicines, relates to a treatment technology for early abortion, and in particular relates to an application of Clostridium prausnitzii (Faecalibacterium prausnitzii) in preparation of a medicine for treating early abortion. An experiment of a Poly (I: C) induced early-stage abortion mouse model proves that the clostridium praeparatum can obviously reduce the embryo loss rate and improve placenta development through oral intragastric administration. The action mechanism is that maternal immune balance is regulated by increasing the proportion of regulatory T cells (Treg) and inhibiting excessive activation of an IL-17 signal channel. As human intestinal symbiotic bacteria, the clostridium praeparatum is high in safety and can be used for intervention of early abortion, especially recurrent abortion, and a new strategy is provided for clinic.

The invention discloses a clostridium aerovorans continuous fermentation method based on multi-parameter regulation and control, and belongs to the technical field of microbial fermentation. The method comprises the following parameter control: fermentation culture medium concentration control: in a biomass stabilization stage, gradually reducing the fermentation culture medium concentration from an initial concentration so as to reduce an acid production ratio and improve an alcohol production ratio; the CO content in the tail gas is controlled, wherein the volume fraction of CO in the tail gas is controlled to be 5-10%, and therefore the growth rate of the clostridium aerovorans is increased; dilution degree control: gradually improving the dilution degree so as to improve the fermentation yield; wherein the dilution is equal to the product of the fermentation culture medium feeding speed and 24 / fermentation liquid volume; a ceramic membrane is added, and thalli are intercepted by adding the ceramic membrane, so that the biomass is improved. According to the method, the fermentation acid-alcohol ratio can be regulated and controlled, and the fermentation rate of the clostridium aerovorans is increased.

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

Present invention relates to a method of treating a disorder by administering an effective amount of a pharmaceutical composition comprising a therapeutic agent bound to a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E (BoNT / E). The p80 is bound to a therapeutic agent, comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. P80 enhances the transportation of the therapeutic agent into the bloodstream for increased bioavailability because thep80 is a tight junction modulator to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery.

The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

This invention relates to the field of microbial technology, specifically to a method for the production and extraction of N-acetylmuroic acid-L-alanine amidase via microbial fermentation. The method for preparing N-acetylmuroic acid-L-alanine amidase provided by this invention utilizes *Clostridium beijerinckii* XH0906 for fermentation to produce N-acetylmuroic acid-L-alanine amidase. As the main extracellular protein of this bacterium, N-acetylmuroic acid-L-alanine amidase has a high yield and is beneficial for subsequent separation and purification. This method has advantages such as simplicity, efficiency, and low cost, providing an effective method for the preparation of N-acetylmuroic acid-L-alanine amidase, and has good application prospects in the fields of microbial food, biomedicine, and antibacterial applications.

The present invention discloses a variant D-allulose 3-epimerase (DAEase) that is distinguished from a wild-type DAEase derived from Spirochaetales bacterium (spDAEase) by at least one amino acid sequence variation comprising substitution of an 5 amino acid residue corresponding to position 69, 119, 138, 175, 203, 208, 229, 240, or 265 of SEQ ID NO. 1; or a variant DAEase that is distinguished from a wild-type DAEase derived from Clostridium cellulolyticum (ccDAEase) by an amino acid sequence variation comprising substitution of an amino acid at position 46 and / or a truncation of C-terminal end of in SEQ ID NO. 2.

According to the present invention, provided is a Clostridium perfringens sporulation inhibitor that contains at least one inorganic compound at such a concentration as to cause the precipitation of C. perfringens in vivo, wherein the inorganic compound is a salt of at least one selected from the group consisting of K, Na, Mg, Ca and Fe and the inorganic compound is coated with a protective layer containing a hardened vegetable oil.

This invention belongs to the field of microbial technology, and relates to a *Pediococcus pentosacchari* strain derived from geese, its isolation and screening method, and its application. The *Pediococcus pentosacchari* strain is *Pediococcus pentosacchari*. Pediococcus pentosaceus L2, deposited at the Guangdong Provincial Microbial Culture Collection Center, accession number GDMCC No:67207. This invention, *Pediococcus pentosaceus* L2, was isolated and screened from the cecum of healthy Magang geese. Its source is reliable and readily available, possessing safety and probiotic properties. It exhibits good antibacterial activity against *Clostridium perfringens*, demonstrating excellent probiotic potential for application in feed additives, probiotic preparations, and medications for treating geese infected with *Clostridium perfringens*.

Provided herein, inter alia, are methods and compositions for the treatment of cancer. The compositions include one or more anti-cancer agents and Clostridium butyricum. Administration of Clostridium butyricum can enhance the therapeutic effects of anti-cancer agents, thereby increasing the efficacy of said agents for cancer treatment.

Methods and compositions for treating cancer are provided.SOLUTION: The compositions comprise one or more anti-cancer agents and Clostridium butyricum. Administration of Clostridium butyricum can increase the therapeutic effect of the anti-cancer agent, thereby increasing the effectiveness of said agent for treating cancer.SELECTED DRAWING: Figure 5

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly to a culture medium composition for culturing Clostridium sp. strains capable of producing botulinum toxin. When a Clostridium botulinum strain is cultured using a culture medium comprising vegetable peptone, glucose, and yeast extract without animal-derived components, the growth rate of the strain is increased compared to existing culture media, and the strain can be safely cultured since animal-derived components are not included, thereby increasing the yield of botulinum toxin.

Shelf-stable packaged low acid-beverages and methods for the same are disclosed. The shelf-stable packaged low acid beverage may include a container and a liquid low acid beverage disposed and sealed in the container. The liquid low acid beverage may include oxygen dissolved therein in an amount sufficient to prevent growth of bacteria, such as Clostridium botulinum or other bacteria such as Psychotrophs or lactic bacteria. The method may include dissolving the liquid low acid beverage into the container, dissolving oxygen and / or nitrogen into the low liquid beverage disposed in the container, and sealing the container. The container and the liquid low acid beverage may define a headspace disposed in the container. The oxygen may be present in the headspace in an amount greater than 0%, or greater than or equal to about 12%, based on the volume of the headspace.

This invention belongs to the field of biotechnology, specifically relating to a hybridoma cell line secreting monoclonal antibodies against Clostridium perfringens ETX and its applications. Based on natural toxins, this invention establishes an indirect ELISA detection method using a non-toxic ETX single-amino acid site protein mutant. A series of hybridoma cell lines secreting monoclonal antibodies against Clostridium perfringens ETX were screened. These hybridoma cell lines can stably and efficiently secrete both neutralizing monoclonal antibodies and non-neutralizing monoclonal antibodies, and can be mass-produced on a large scale. This invention is the first to establish an antigen ELISA detection method for Clostridium perfringens ETX using monoclonal antibodies. This method features simple sample handling, low cost, rapid reaction, and high specificity. It can also provide a reference for the diagnosis of Clostridium perfringens infection and lay the foundation for research on alternative methods for testing the efficacy of related vaccines.

Compounds for use in the treatment of Clostridium difficile infection A compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use as medicament, wherein each

The invention discloses application of beta-nicotinamide mononucleotide in preparation of a medicine for inhibiting clostridium difficile infection, and relates to the technical field of biomedicine. The invention discloses application of beta-nicotinamide mononucleotide in preparation of a medicine for inhibiting intestinal diseases caused by clostridium difficile infection. According to the invention, the beta-nicotinamide mononucleotide realizes systematic intervention on clostridium difficile infection through a dual core mechanism of down-regulating the expression of a proinflammatory factor and inhibiting a pyroptosis pathway mediated by metronidatin D; the anti-infection survival ability of a host can be remarkably enhanced, intestinal inflammation injury is relieved, the occurrence risk of complications such as pseudomembranous colitis is reduced, and the defect that dysbacteriosis is aggravated by traditional antibiotics is avoided; a brand new intervention strategy is provided for the public health emergency threat disease, namely, clostridium difficile infection, a foundation is laid for expanded application of beta-nicotinamide mononucleotide in the field of intestinal inflammatory diseases, and the beta-nicotinamide mononucleotide has prominent clinical transformation potential and academic research value.

The invention relates to the technical field of wine brewing, and particularly discloses a microbial liquid for improving the quality of Maotai-flavor liquor and application thereof.Through the synergistic effect of three microbial agents, a continuous metabolic complementary network is formed in a brewing system, and clostridium tyrobutyricum provides organic acid and part of precursor substances in the anaerobic stage; the issatchenkia orientalis dominates alcoholic fermentation and synthesis of main esters, and creates a chemical environment beneficial to metabolism of other strains; the staphylococcus saprophyticus enhances protein conversion and generation of special flavor substances. According to the method, the metabolic pathways of acids, esters, pyrazines and phenols in a brewing system are enhanced, so that key flavor substances of the Maotai-flavor liquor are systematically improved, the fragrance of the liquor body is stronger and more harmonious, the taste is more mellow and full, and the overall quality is remarkably improved.

A novel vaccine and methods of preventing and treating C. difficile infection in a patient is described. The vaccine is comprised of a fusion protein (denoted FliCD) comprised of the FliC and FliD from C. difficile and joined by a linker sequence. Administration of the vaccine, as well as anti-FliCD serum, has been shown to prevent C. difficile infection as well as treat existing infections.

The application discloses a method for producing hydrogen through Clostridium pasteurianum-Rhodobacter sphaeroides coupling fermentation based on nitrogen limitation and application thereof. In the method, activated Clostridium pasteurianum is subjected to dark fermentation for producing hydrogen in a nitrogen-free culture medium and in an argon environment; then, the pH value of the obtained culture solution is adjusted to 7.0-8.0, the activated Rhodobacter sphaeroides is inoculated after selective sterilization, and the light fermentation for producing hydrogen is carried out in the argon environment. In the application, the fermentation solution of Clostridium pasteurianum does not need to be subjected to centrifugal removal of bacterial bodies and the like, and only needs to be simply adjusted in pH value, so that the light fermentation for producing hydrogen of Rhodobacter sphaeroides can be directly carried out. In the application, the nitrogen limitation is used to inhibit excessive proliferation of bacterial bodies, save carbon source flow, induce high expression of nitrogen fixation enzyme, and open a second high-efficiency hydrogen production path in addition to hydrogenase, so that the hydrogen production yield is further improved while the cost of nitrogen source is reduced. The hydrogen production yield of the application reaches 9.81 mol H2 / mol glucose, which is the highest level at present.

The invention discloses a method for fermenting trachinotus ovatus by-products through clostridium butyricum, high-value products and application, and belongs to the technical field of microbial fermentation and resource utilization. According to the method, the trachinotus ovatus processing byproduct is directly used as a fermentation substrate, and the composition of a clostridium butyricum fermentation culture medium and fermentation conditions are systematically optimized through a response surface method, so that an efficient fermentation process is established. By adopting the technology, the trachinotus ovatus byproduct is converted into a high-added-value fermentation product. Experimental results show that compared with a control group, the biomass of clostridium butyricum in a fermentation product is increased by 13%, the content of butyric acid is increased by 102.5%, and the contents of n-valeric acid, isovaleric acid and hexanoic acid are all remarkably increased in a breakthrough manner; the total antioxidant capacity of a fermentation product is improved by 67%, and the activity of superoxide dismutase and the activity of catalase are improved by 105% and 83.9% respectively. According to the method, high-value utilization of aquatic byproducts is realized, and the obtained product can be applied to the fields of feeds, functional foods and the like.

This invention provides a Ganoderma lucidum β-glucan oligosaccharide synbiotic composition and its application, belonging to the field of microbial preparation technology. The synbiotic composition provided by this invention includes prebiotics and probiotics. The prebiotics include Ganoderma lucidum β-glucan oligosaccharide, and the probiotics include Bacteroides monotypica and Clostridium butyricum. The synbiotic composition provided by this invention can effectively reduce inflammation, improve oxidative stress, and significantly increase the content of SCFAs in the gut microbiota, exhibiting a synergistic effect in all these aspects. The Ganoderma lucidum β-glucan oligosaccharide provided by this invention shows the best growth-promoting and metabolic effects on Bacteroides monotypica and Clostridium butyricum. After combining the three, the butyric acid yield reaches 20.99 mM, significantly better than single strains and other compound combinations, providing a scientific basis for developing precisely targeted synbiotic products. Moreover, the synbiotic composition of this invention can reduce the side effects such as gastrointestinal bloating caused by traditional prebiotics, making it suitable for long-term use.

A Clostridium sp. bacterium and the use thereof. The bacterium can completely metabolize 2000μg / mL of uric acid in a culture medium within 8 hours. In vivo experiments show that the bacterium can significantly reduce the contents of uric acid in serum and urine of mice with hyperuricemia.

The invention relates to an application of probiotics, and provides an application of clostridium butyricum MIYAIRI 588 viable bacteria (CBM 588) in preparation of a preparation for preventing and treating calcium oxalate kidney stone, and particularly relates to an application of the clostridium butyricum MIYAIRI 588 viable bacteria (CBM 588) in preparation of a preparation for preventing and treating calcium oxalate kidney stone. The formulation can be an orally administered formulation, and the viable bacteria can be dispersed in an aqueous carrier to form a solution or suspension. Animal model experiments show that the clostridium butyricum treatment can reduce kidney crystal or calcium salt deposition related characterization, reduce serum creatinine and urea nitrogen, regulate intestinal flora structure, improve expression of ileum tight junction protein ZO-1 and occludin, reduce serum endotoxin level and reduce the content of glycohyodeoxycholic acid in excrement, serum and kidney, and can be used for treating the kidney and the kidney. A novel preparation application is provided for preventing and treating the calcium oxalate kidney stone.

This invention belongs to the field of microbial and genetic engineering technology, specifically relating to a genetically engineered *C. yongdar* strain and its application in the synthesis of ethanol, lactic acid, and 2,3-butanediol from one-carbon gas fermentation. This invention proposes a strategy for metabolic modification of *C. yongdar* based on the lactate cycle. Three engineered strains were constructed by knocking out lactate dehydrogenase (LDH) producing lactate, knocking out lactate dehydrogenase oxidizing lactate, and overexpressing LDH producing lactate dehydrogenase based on the knockout of lactate dehydrogenase oxidizing lactate. This modification strategy can increase the yield of 2,3-butanediol, ethanol, and lactic acid in the one-carbon gas autotrophic fermentation of *C. yongdar*, providing a feasible metabolic modification technology for the syngas fermentation of acetic acid-producing bacteria to produce high-value compounds, thus possessing good practical application value.

Provided are methods for repairing a wound or inducing the proliferative phase of a wound comprising administering a composition comprising a protease mixture comprising collagenases and a neutral protease to the wound in an amount effective for repair of wound tissue or for inducing the proliferative phase in the wound.

The invention relates to an application of a microbial polypeptide derived from clostridium acetobutylicum in preparation of an anti-tumor vaccine, and belongs to the technical field of biological medicines and tumor immunotherapy medicines. In order to solve the problem of lack of adaptive microbial polypeptides which can be effectively applied to preparation of tumor vaccines at present, the invention provides application of a microbial polypeptide derived from clostridium acetobutylicum in preparation of anti-tumor vaccines, and the amino acid sequence of the microbial polypeptide is as shown in SEQ ID No: 1; as a core active component of an anti-tumor vaccine, the compound has remarkable immunogenicity and anti-tumor effect, can reduce immune tolerance, efficiently activates CD8 + T cells and has a better tumor cell killing effect. The microbial polypeptide is a universal antigen, does not need individual customization, can cover 14 TP53G105V mutation related tumors, has treatment and prevention potentials, can induce anti-tumor immunity to treat tumors, and can also be used for tumor prevention of high-risk people.